SCHEMBL4767133

SCHEMBL4767133

CCOc1ccc2c(c1-c1cccc3ccccc13)[CH]c1ccccc1-2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.46
S1PR3 Q99500 1/20 0.46
ALOX5 P09917 1/20 0.42
ENPP1 P22413 1/20 0.40
DHFR P00374 1/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
PDK2 Q15119 1/20 0.35
ALDH1A1 P00352 4/20 0.35
RAB9A P51151 2/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
FDPS P14324 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRNB4 P30926 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723334 0.90 CNR1 (0.43) S1PR1S1PR3TSHRMEN1KMT2A
SCHEMBL4723465 0.89 GAA (0.45)
SCHEMBL4721475 0.85 MAPT (0.50) DHFRALDH1A1RAB9ALMNAMEN1
SCHEMBL4722390 0.81 ALDH1A1 (0.38) ALOX5PDK2ALDH1A1RAB9AHSD17B10
SCHEMBL29473526 0.80 ALOX5 (0.57) S1PR1S1PR3ALOX5ENPP1DHFR
SCHEMBL12223406 0.80 ALOX5 (0.57) S1PR1S1PR3ALOX5ENPP1DHFR
SCHEMBL218825 0.80 KDM4E (0.36) DHFRALDH1A1RAB9ATSHRHSD17B10
SCHEMBL218380 0.77 DHFR (0.44) ENPP1DHFRALDH1A1RAB9ATSHR
SCHEMBL218535 0.77 ELANE (0.34) DHFRALDH1A1TSHRHSD17B10
SCHEMBL4921197 0.77 ALDH1A1 (0.48) ENPP1PDK2ALDH1A1MAPTADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 S1PR1 618/4885S1PR3 346/4885ALOX5 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.